William Blair Issues Negative Estimate for Incyte Earnings

Incyte Corporation (NASDAQ:INCY) – William Blair dropped their Q2 2025 earnings per share (EPS) estimates for shares of Incyte in a note issued to investors on Monday, July 14th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $1.06 for the quarter, down from their prior forecast of $1.11. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte’s FY2025 earnings at $4.55 EPS and FY2026 earnings at $5.75 EPS.

Several other research firms also recently weighed in on INCY. Royal Bank Of Canada set a $67.00 target price on Incyte and gave the company a “sector perform” rating in a research report on Monday, June 23rd. Guggenheim cut shares of Incyte from a “buy” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research note on Tuesday, March 18th. Wells Fargo & Company increased their target price on shares of Incyte from $58.00 to $59.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 30th. JPMorgan Chase & Co. decreased their price target on shares of Incyte from $68.00 to $67.00 and set a “neutral” rating on the stock in a research note on Monday. Finally, Truist Financial upped their price objective on shares of Incyte from $72.00 to $73.00 and gave the company a “hold” rating in a research note on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Incyte has a consensus rating of “Hold” and a consensus price target of $74.47.

Incyte Trading Down 2.5%

Shares of Incyte stock opened at $68.25 on Tuesday. The company has a current ratio of 2.04, a quick ratio of 2.00 and a debt-to-equity ratio of 0.01. Incyte has a twelve month low of $53.56 and a twelve month high of $83.95. The firm has a market capitalization of $13.21 billion, a PE ratio of 213.29, a P/E/G ratio of 0.59 and a beta of 0.68. The firm’s 50-day moving average price is $66.56 and its 200 day moving average price is $66.63.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.15. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $996.17 million. Incyte had a net margin of 0.48% and a return on equity of 2.77%. The company’s revenue was up 19.5% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share.

Institutional Trading of Incyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INCY. Banque Transatlantique SA acquired a new stake in shares of Incyte in the first quarter valued at $26,000. Raiffeisen Bank International AG purchased a new position in Incyte during the 4th quarter valued at about $34,000. SVB Wealth LLC acquired a new position in Incyte in the 1st quarter valued at about $39,000. Geneos Wealth Management Inc. increased its stake in Incyte by 350.0% during the first quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 588 shares during the period. Finally, WPG Advisers LLC acquired a new stake in shares of Incyte during the first quarter worth about $47,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Buying and Selling

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the transaction, the executive vice president owned 26,504 shares of the company’s stock, valued at $1,818,439.44. This represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Vijay K. Iyengar sold 8,617 shares of Incyte stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $587,248.55. Following the sale, the executive vice president owned 37,701 shares of the company’s stock, valued at approximately $2,569,323.15. This represents a 18.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,119 shares of company stock valued at $1,371,385. 17.80% of the stock is currently owned by insiders.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.